Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Pallavi Madhiraju- November 7, 2024 0

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline's Arexvy vaccine to include adults aged 50 to 59 who ... Read More